$NVCR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NovoCure Ltd. Get notifications about new insider transactions in NovoCure Ltd for free.
Page: < prev 1 2 3 4 5 6 ... 10 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 22 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 158.09 | 9,183 | 1,451,777 | 221,850 | 231 K to 221.9 K (-3.97 %) |
| Dec 22 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 157.04 | 24,656 | 3,871,904 | 231,033 | 255.7 K to 231 K (-9.64 %) |
| Dec 22 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 156.09 | 24,286 | 3,790,826 | 255,689 | 280 K to 255.7 K (-8.67 %) |
| Dec 22 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 155.24 | 21,612 | 3,355,047 | 279,975 | 301.6 K to 280 K (-7.17 %) |
| Dec 22 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 22.00 | 103,955 | 2,287,010 | 301,587 | 197.6 K to 301.6 K (+52.60 %) |
| Nov 03 2020 | NVCR | NovoCure Ltd | Cordova Ashley | Chief Financial Off ... | Sell | S | 117.41 | 230 | 27,005 | 26,212 | 26.4 K to 26.2 K (-0.87 %) |
| Sep 28 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Option Exercise | M | 7.15 | 6,500 | 46,475 | 6,500 | |
| Sep 28 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Option Exercise | M | 11.46 | 8,750 | 100,275 | 0 | |
| Sep 28 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Sell | S | 103.35 | 6,500 | 671,775 | 27,597 | 34.1 K to 27.6 K (-19.06 %) |
| Sep 28 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Buy | M | 7.15 | 6,500 | 46,475 | 34,097 | 27.6 K to 34.1 K (+23.55 %) |
| Sep 28 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Sell | S | 103.35 | 8,750 | 904,313 | 27,597 | 36.3 K to 27.6 K (-24.07 %) |
| Sep 28 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Buy | M | 11.46 | 8,750 | 100,275 | 36,347 | 27.6 K to 36.3 K (+31.71 %) |
| Sep 21 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.48 | 8,262 | 61,800 | 0 | |
| Sep 21 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 110.89 | 200 | 22,177 | 142,607 | 142.8 K to 142.6 K (-0.14 %) |
| Sep 21 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 110.24 | 1,813 | 199,865 | 142,807 | 144.6 K to 142.8 K (-1.25 %) |
| Sep 21 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 109.23 | 3,536 | 386,223 | 144,620 | 148.2 K to 144.6 K (-2.39 %) |
| Sep 21 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 108.49 | 2,513 | 272,645 | 148,156 | 150.7 K to 148.2 K (-1.67 %) |
| Sep 21 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.92 | 200 | 21,383 | 150,669 | 150.9 K to 150.7 K (-0.13 %) |
| Sep 21 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.48 | 8,262 | 61,800 | 150,869 | 142.6 K to 150.9 K (+5.79 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.48 | 12,500 | 93,500 | 8,262 | |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.48 | 12,500 | 93,500 | 20,762 | |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.03 | 7,579 | 53,280 | 0 | |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.03 | 1,933 | 13,589 | 0 | |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 110.52 | 100 | 11,052 | 142,607 | 142.7 K to 142.6 K (-0.07 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 109.81 | 1,500 | 164,708 | 142,707 | 144.2 K to 142.7 K (-1.04 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 108.79 | 7,868 | 855,960 | 144,207 | 152.1 K to 144.2 K (-5.17 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 107.94 | 2,232 | 240,911 | 152,075 | 154.3 K to 152.1 K (-1.45 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.68 | 500 | 53,341 | 154,307 | 154.8 K to 154.3 K (-0.32 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 105.28 | 300 | 31,585 | 154,807 | 155.1 K to 154.8 K (-0.19 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.48 | 12,500 | 93,500 | 155,107 | 142.6 K to 155.1 K (+8.77 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 109.54 | 600 | 65,725 | 142,607 | 143.2 K to 142.6 K (-0.42 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 108.71 | 1,700 | 184,805 | 143,207 | 144.9 K to 143.2 K (-1.17 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 107.66 | 5,123 | 551,558 | 144,907 | 150 K to 144.9 K (-3.41 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.67 | 3,077 | 328,224 | 150,030 | 153.1 K to 150 K (-2.01 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 105.80 | 2,000 | 211,600 | 153,107 | 155.1 K to 153.1 K (-1.29 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.48 | 12,500 | 93,500 | 155,107 | 142.6 K to 155.1 K (+8.77 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 109.55 | 400 | 43,822 | 142,607 | 143 K to 142.6 K (-0.28 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 108.57 | 1,000 | 108,569 | 143,007 | 144 K to 143 K (-0.69 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 107.65 | 3,279 | 352,978 | 144,007 | 147.3 K to 144 K (-2.23 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.55 | 2,100 | 223,753 | 147,286 | 149.4 K to 147.3 K (-1.41 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 105.62 | 800 | 84,493 | 149,386 | 150.2 K to 149.4 K (-0.53 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.03 | 7,579 | 53,280 | 150,186 | 142.6 K to 150.2 K (+5.31 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 109.16 | 200 | 21,831 | 142,607 | 142.8 K to 142.6 K (-0.14 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 107.97 | 600 | 64,784 | 142,807 | 143.4 K to 142.8 K (-0.42 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 107.18 | 633 | 67,847 | 143,407 | 144 K to 143.4 K (-0.44 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.05 | 500 | 53,026 | 144,040 | 144.5 K to 144 K (-0.35 %) |
| Sep 18 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.03 | 1,933 | 13,589 | 144,540 | 142.6 K to 144.5 K (+1.36 %) |
| Sep 17 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 22.00 | 103,000 | 2,266,000 | 207,910 | |
| Sep 17 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 99.00 | 103,000 | 10,197,000 | 197,632 | 300.6 K to 197.6 K (-34.26 %) |
| Sep 17 2020 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 22.00 | 103,000 | 2,266,000 | 300,632 | 197.6 K to 300.6 K (+52.12 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 7.48 | 7,392 | 55,292 | 0 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 7.48 | 2,173 | 16,254 | 0 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 7.48 | 10,000 | 74,800 | 2,173 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 100.00 | 7,392 | 739,200 | 72,045 | 79.4 K to 72 K (-9.31 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 7.48 | 7,392 | 55,292 | 79,437 | 72 K to 79.4 K (+10.26 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 100.00 | 2,173 | 217,300 | 72,045 | 74.2 K to 72 K (-2.93 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 7.48 | 2,173 | 16,254 | 74,218 | 72 K to 74.2 K (+3.02 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 95.00 | 10,000 | 950,000 | 72,045 | 82 K to 72 K (-12.19 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 7.48 | 10,000 | 74,800 | 82,045 | 72 K to 82 K (+13.88 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.03 | 12,500 | 87,875 | 7,579 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.48 | 13,368 | 99,993 | 0 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.03 | 12,500 | 87,875 | 1,933 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.48 | 12,500 | 93,500 | 33,262 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.03 | 12,500 | 87,875 | 14,433 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | M | 7.03 | 12,500 | 87,875 | 20,079 | |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.02 | 2,334 | 247,444 | 142,607 | 144.9 K to 142.6 K (-1.61 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 104.69 | 10,166 | 1,064,228 | 144,941 | 155.1 K to 144.9 K (-6.55 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.48 | 12,500 | 93,500 | 155,107 | 142.6 K to 155.1 K (+8.77 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 104.45 | 13,368 | 1,396,288 | 142,607 | 156 K to 142.6 K (-8.57 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.48 | 13,368 | 99,993 | 155,975 | 142.6 K to 156 K (+9.37 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 99.33 | 2,197 | 218,232 | 142,607 | 144.8 K to 142.6 K (-1.52 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 98.50 | 1,900 | 187,142 | 144,804 | 146.7 K to 144.8 K (-1.30 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.33 | 300 | 31,900 | 146,704 | 147 K to 146.7 K (-0.20 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 105.53 | 700 | 73,870 | 147,004 | 147.7 K to 147 K (-0.47 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 104.53 | 2,203 | 230,282 | 147,704 | 149.9 K to 147.7 K (-1.47 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 103.75 | 1,700 | 176,373 | 149,907 | 151.6 K to 149.9 K (-1.12 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 102.58 | 1,200 | 123,092 | 151,607 | 152.8 K to 151.6 K (-0.79 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 101.20 | 1,200 | 121,444 | 152,807 | 154 K to 152.8 K (-0.78 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 100.28 | 1,100 | 110,304 | 154,007 | 155.1 K to 154 K (-0.71 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.03 | 12,500 | 87,875 | 155,107 | 142.6 K to 155.1 K (+8.77 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 99.33 | 2,200 | 218,522 | 142,607 | 144.8 K to 142.6 K (-1.52 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 98.48 | 1,900 | 187,112 | 144,807 | 146.7 K to 144.8 K (-1.30 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 106.39 | 300 | 31,916 | 146,707 | 147 K to 146.7 K (-0.20 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 105.54 | 600 | 63,323 | 147,007 | 147.6 K to 147 K (-0.41 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 104.55 | 2,193 | 229,285 | 147,607 | 149.8 K to 147.6 K (-1.46 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 103.76 | 1,800 | 186,773 | 149,800 | 151.6 K to 149.8 K (-1.19 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 102.55 | 1,200 | 123,054 | 151,600 | 152.8 K to 151.6 K (-0.79 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 101.19 | 1,207 | 122,133 | 152,800 | 154 K to 152.8 K (-0.78 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 100.27 | 1,100 | 110,301 | 154,007 | 155.1 K to 154 K (-0.71 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.48 | 12,500 | 93,500 | 155,107 | 142.6 K to 155.1 K (+8.77 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 98.01 | 12,500 | 1,225,125 | 142,607 | 155.1 K to 142.6 K (-8.06 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.03 | 12,500 | 87,875 | 155,107 | 142.6 K to 155.1 K (+8.77 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 98.01 | 12,500 | 1,225,088 | 142,607 | 155.1 K to 142.6 K (-8.06 %) |
| Sep 16 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Buy | M | 7.03 | 12,500 | 87,875 | 155,107 | 142.6 K to 155.1 K (+8.77 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 86.07 | 700 | 60,252 | 70,465 | 71.2 K to 70.5 K (-0.98 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 85.39 | 27,621 | 2,358,629 | 71,165 | 98.8 K to 71.2 K (-27.96 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 7.48 | 10,000 | 74,800 | 12,173 | |
| Sep 11 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 7.03 | 9,114 | 64,071 | 0 | |
| Sep 11 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 90.00 | 10,000 | 900,000 | 72,045 | 82 K to 72 K (-12.19 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 7.48 | 10,000 | 74,800 | 82,045 | 72 K to 82 K (+13.88 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 86.06 | 100 | 8,606 | 72,045 | 72.1 K to 72 K (-0.14 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 85.39 | 9,014 | 769,687 | 72,145 | 81.2 K to 72.1 K (-11.11 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 7.03 | 9,114 | 64,071 | 81,159 | 72 K to 81.2 K (+12.65 %) |
| Sep 04 2020 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development O ... | Option Exercise | A | 84.68 | 11,336 | 959,932 | 11,336 | |
| Sep 04 2020 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development O ... | Grant | A | 0.00 | 5,904 | 0 | 81,633 | 75.7 K to 81.6 K (+7.80 %) |
| Sep 04 2020 | NVCR | NovoCure Ltd | Cordova Ashley | Chief Financial Off ... | Option Exercise | A | 84.68 | 11,336 | 959,932 | 11,336 | |
| Sep 04 2020 | NVCR | NovoCure Ltd | Cordova Ashley | Chief Financial Off ... | Grant | A | 0.00 | 5,904 | 0 | 26,442 | 20.5 K to 26.4 K (+28.75 %) |
| Sep 04 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 7.03 | 100 | 703 | 9,114 | |
| Sep 04 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 85.00 | 100 | 8,500 | 72,045 | 72.1 K to 72 K (-0.14 %) |
| Sep 04 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 7.03 | 100 | 703 | 72,145 | 72 K to 72.1 K (+0.14 %) |
| Sep 03 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Option Exercise | A | 84.68 | 3,779 | 320,006 | 3,779 | |
| Sep 03 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Grant | A | 0.00 | 1,968 | 0 | 27,597 | 25.6 K to 27.6 K (+7.68 %) |
| Sep 03 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Option Exercise | A | 84.68 | 3,779 | 320,006 | 3,779 | |
| Sep 03 2020 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Science Offic ... | Grant | A | 0.00 | 1,968 | 0 | 27,597 | 25.6 K to 27.6 K (+7.68 %) |
| Sep 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 84.68 | 3,779 | 320,006 | 3,779 | |
| Sep 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | P | 85.01 | 4,200 | 357,054 | 98,786 | 103 K to 98.8 K (-4.08 %) |
| Sep 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 0.00 | 1,968 | 0 | 102,986 | 101 K to 103 K (+1.95 %) |
| Sep 03 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Option Exercise | A | 84.68 | 3,779 | 320,006 | 3,779 | |
| Sep 03 2020 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Grant | A | 0.00 | 1,968 | 0 | 142,607 | 140.6 K to 142.6 K (+1.40 %) |
| Aug 05 2020 | NVCR | NovoCure Ltd | Madden Martin J. | Director | Grant | A | 0.00 | 307 | 0 | 307 | 0 to 307 |
| Aug 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 76.81 | 2,048 | 157,307 | 101,018 | 103.1 K to 101 K (-1.99 %) |
| Aug 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 76.41 | 1,669 | 127,522 | 103,066 | 104.7 K to 103.1 K (-1.59 %) |
| Aug 05 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 76.06 | 660 | 50,200 | 29,356 | 30 K to 29.4 K (-2.20 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 76.39 | 341 | 26,048 | 30,016 | 30.4 K to 30 K (-1.12 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Grant | A | 50.41 | 325 | 16,382 | 30,357 | 30 K to 30.4 K (+1.08 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 76.39 | 896 | 68,444 | 649,062 | 650 K to 649.1 K (-0.14 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 7.03 | 7,112 | 49,997 | 7,112 | |
| Aug 03 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 75.00 | 7,112 | 533,400 | 72,045 | 79.2 K to 72 K (-8.98 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 7.03 | 7,112 | 49,997 | 79,157 | 72 K to 79.2 K (+9.87 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 3,717 | 0 | 3,717 | |
| Aug 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 76.17 | 3,717 | 283,124 | 104,735 | 101 K to 104.7 K (+3.68 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 21.15 | 30,772 | 650,828 | 67,586 | |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 11.46 | 3,774 | 43,250 | 0 | |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 11.46 | 8,426 | 96,562 | 0 | |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 21.15 | 3,021 | 63,894 | 98,358 | |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 11.46 | 300 | 3,438 | 8,426 | |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 67.39 | 17,175 | 1,157,475 | 220,867 | 238 K to 220.9 K (-7.22 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 66.66 | 12,217 | 814,336 | 238,042 | 250.3 K to 238 K (-4.88 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 65.49 | 1,380 | 90,375 | 250,259 | 251.6 K to 250.3 K (-0.55 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 21.15 | 30,772 | 650,828 | 251,639 | 220.9 K to 251.6 K (+13.93 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 67.28 | 2,623 | 176,470 | 220,867 | 223.5 K to 220.9 K (-1.17 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 66.50 | 1,151 | 76,539 | 223,490 | 224.6 K to 223.5 K (-0.51 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 11.46 | 3,774 | 43,250 | 224,641 | 220.9 K to 224.6 K (+1.71 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 67.48 | 3,798 | 256,274 | 220,867 | 224.7 K to 220.9 K (-1.69 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 66.77 | 4,228 | 282,287 | 224,665 | 228.9 K to 224.7 K (-1.85 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 65.53 | 400 | 26,210 | 228,893 | 229.3 K to 228.9 K (-0.17 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 11.46 | 8,426 | 96,562 | 229,293 | 220.9 K to 229.3 K (+3.81 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 65.06 | 3,021 | 196,552 | 220,867 | 223.9 K to 220.9 K (-1.35 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 21.15 | 3,021 | 63,894 | 223,888 | 220.9 K to 223.9 K (+1.37 %) |
| Jul 23 2020 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 65.07 | 300 | 19,520 | 220,867 | 221.2 K to 220.9 K (-0.14 %) |